ir.apricusbio.com
Investor Home | Investors | Apricus Biosciences
Mission / Vision / Values. Annual Meeting of Stockholders. Apricus Biosciences, Inc. at the Canaccord Genuity 35th Annual Growth Conference. 160;at 10:00 am ET. Apricus Biosciences, Inc. at the Canaccord Genuity 35th Annual Growth Conference. Wednesday, August 12, 2015 . 10:00 am ET . Click here for webcast. Click here to add this event to your calendar. Apricus Biosciences Announces Approval of Vitaros(R) for the Treatment of Erectile Dysfunction in Twelve Additional Countries. RayVa Phase 2a Trial Top...
ir.aptevotherapeutics.com
Investor Home : Investors : Aptevo
Aptevo Therapeutics and the ADAPTIR (Modular Protein Technology) Platform: The Future of Immuno-oncology. 160; 0.08 (3.21%). Updated January 13, 2017 4:00 pm ET. Stacey L. Jurchison. Senior Director, Investor Relations and Corporate Communications. Aptevo Therapeutics Inc at 29th Annual ROTH Conference. Aptevo Therapeutics Inc at the 16th Annual PEPTALK Conference. Aptevo Therapeutics Inc at Piper Jaffray 28th Annual Healthcare Conference.
ir.aptg.com.tw
A+ Asia Pacific Telecom Website
ir.aptose.com
Aptose Biosciences - Investors - Overview
SELECT SOLID TUMOR INDICATIONS. CDX2 AND KRUPPEL-LIKE FACTOR BIOLOGY. Aptose Biosciences, Inc. at 9th Annual Biotech Showcase. January 10, 2017. 160;at 9:00 am PT. Aptose Biosciences, Inc. at 9th Annual Biotech Showcase. Tuesday, January 10, 2017 . 9:00 am PT . Click here for webcast. Click here to add this event to your calendar. January 5, 2017. Aptose Biosciences to Present at Biotech Showcase 2017 Conference. December 29, 2016. Aptose Biosciences Provides Update on APTO-253 Development.
ir.aqr.com
AQR Capital - Investor Relations - Overview
Investor and Media Contact. There are currently no news releases. Primary IR and Media Contact. Quotes delayed at least 15 minutes. Market data provided by Interactive Data. Powered and implemented by Interactive Data Managed Solutions.
ir.aquaamerica.com
Investor Relations | Aqua America
Skip to main navigation. Reconciliation of GAAP to Non-GAAP Financial Measures. Regulated segment - Efficiency ratio adjusted for purchased water. Reconciliation of GAAP to Non-GAAP financial measures - EBITDA reconciliation for continuing operations. Adjusted Net Income EPS Q4 2017. Dividend Reinvestment and DSPP. There are currently no events to display. Feb 27, 2018. Aqua America Reports Earnings for 2017, Announces 2018 Guidance. Feb 5, 2018. Aqua America Declares March 2018 Dividend. Feb 1, 2018.
ir.arafaholding.com
Arafa Holding | Investor Relations
Board and Shareholders Actions. Share and Corporate Information. Luxury, Formal and Casual Wear across own brands. Textiles, Apparel and Tailoring, Retail and Distribution. Concrete, with 47 retail stores nationwide across Egypt. Learn about Arafa Holding's business model, strategy, brands and partnerships through our downloadable presentations in the Presentations and Publications center. As of 16:02, on Thu, Aug, 13 2015. Arafa Earnings Release 1Q2015. Arafa Holding Financials 1Q2015 (Arabic).
ir.arcadis.com
Arcadis Investors - ARCADIS NV - Investor Relations
United Kingdom (ARCADIS AYH). ARCADIS at a Glance. Reasons to invest in ARCADIS. Share Quote and Chart. Risk and Risk Management. IR Team and Subscriptions. To opt-in to receive our quarterly retail investor newsletter. ARCADIS Q2 2015 Results. Jul 29, 2015 at 3:00 PM CET. Tetra Tech, Inc. 07 Aug 2015 latest: 17:35 CET. Euro; 22.38. Amounts in € millions unless otherwise stated. Organic gross revenue growth. Organic net revenue growth. Net income per share (in €). Net income from operations.
ir.archcapgroup.com
Arch > Investor Information
Earnings Releases and Supplements. Non-US. Subsidiary Information. 07/30/2015 11:00 AM ET. Q2 2015 Arch Capital Group Earnings Conference Call. As of August 14, 2015 -. Minimum 20 minute delay. Q2 2015 Arch Capital Group Earnings Conference Call. Thursday, July 30, 2015. We seek to increase shareholder value through three main strategic principles:. Selectively pursue diverse specialty markets where we can apply our knowledge and expertise;. Maintain a disciplined underwriting approach to enable us to se...
ir.archtherapeutics.com
Overview :: Arch Therapeutics, Inc. (ARTH)
View our latest Corporate Presentation. Go to Detailed Stock Info ›. Arch Therapeutics Announces Private Placement. Arch Therapeutics Obtains Additional Safety Data for Its AC5 Surgical Hemostatic Device(TM) in Successful Preclinical Toxicity Test. Arch Therapeutics Initiates Research and Development Collaboration With CURAM Centre for Research in Medical Devices. Go to Press Releases ›. Visit our FAQs for commonly asked questions and answers. 1859 Whitney Mesa Dr. Henderson, NV 89014.
